In This Article:
Trinity Biotech plc TRIB has announced the acquisition of privately held Irish deep-tech company Metabolomics Diagnostics. The acquired company specializes in the development of novel biomarker-based diagnostic solutions for complex diseases and is likely to improve diagnostic accuracy using mass spectrometry and machine learning for Trinity Biotech.
Trinity Biotech’s deal values Metabolomics Diagnostics at approximately $1.3 million. Trinity Biotech will pay the amount with just over 270,000 Trinity Biotech plc’s American Depositary Shares and the rest in cash and assumption of liabilities.
Trinity Biotech's acquisition of Metabolomics Diagnostics will expedite the U.S. commercialization of the PrePsia preeclampsia test, which leverages mass spectrometry and machine learning for personalized risk assessment. This technology will enhance Trinity's existing maternal health diagnostics and serve as a long-term growth driver alongside its continuous glucose monitoring technology.
The acquisition aligns with Trinity's strategy to integrate its manufacturing expertise and Immco reference lab with Metabolomics’ advanced analytics and bioinformatics, enabling the company to address significant healthcare challenges and improve patient outcomes.
Likely Trend of TRIB Stock Following the News
Following the news release, shares of TRIB rose 4.8% to $1.31 in after-hours trading yesterday. The recent acquisition is expected to enhance Trinity Biotech's diagnostics for complex diseases and diabetes management solutions.
Significance of Trinity Biotech’s Acquisition of Metabolomics
This acquisition is crucial for Trinity Biotech as it will add advanced mass spectrometry and machine learning to its diagnostics platform. The expertise from Metabolomics Diagnostics will expand Trinity's innovation pipeline and tackle significant maternal health issues like preeclampsia. The PrePsia test can predict preeclampsia as early as the 12th week of pregnancy, potentially reducing premature births and improving maternal-fetal outcomes. By enhancing its diagnostic offerings, Trinity is well-positioned for long-term growth in both maternal health and diabetes management markets.
Trinity Biotech's robust manufacturing and regulatory expertise will facilitate the quick launch of a maternal risk screening platform, including crucial preeclampsia diagnostics, through its U.S.-based Immco lab.
More on PrePsia Preeclampsia Test
In 2023, the United States recorded 3.6 million births, with preeclampsia impacting up to 5% of pregnancies. This serious maternal health condition can threaten the lives of mothers and babies. Diagnosed at around 20 weeks through blood pressure and kidney function tests, preeclampsia often lacks effective treatments, resulting in medically induced deliveries in about 30% of cases, leading to premature births.